指南与共识肝病

MAFLD:代谢相关脂肪性肝病共识命名建议

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
指南 / 共识 · Gastroenterology · 2020-02-08

该共识由专家小组提出,认为非酒精性脂肪性肝病(NAFLD)这一术语未能反映当前对代谢功能障碍相关脂肪性肝病的认识。专家达成共识,建议采用「MAFLD」作为更合适的总体术语,以促进疾病亚型划分和药物研发。

要点

  • NAFLD术语未反映当前对代谢功能障碍相关脂肪性肝病的认识。
  • 专家共识建议采用MAFLD作为更合适的总体术语。
  • 新命名有助于疾病亚型划分和加速新药研发。

核心结论

  • 专家共识认为NAFLD不能反映当前知识,建议用MAFLD作为更合适的总体术语。

研究设计与样本

  • 专家小组共识,旨在整合对NAFLD缩写所涵盖患者异质性的当前理解并提出术语建议。

主要发现

  • 与代谢功能障碍相关的脂肪肝常见,影响四分之一人口,且无获批药物疗法。
  • 尽管药物疗法在研发中,但应答率似乎不高。
  • 代谢性脂肪肝病的异质性发病机制及术语和定义的不准确需要重新评估命名。

临床怎么用

  • 采用MAFLD术语可能有助于患者分层管理、临床试验设计和药物开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease "MAFLD" was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020. PMID: 32044314. doi:10.1053/j.gastro.2019.11.312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。